Trial Profile
Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase 0
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms PARTIST
- 23 Jun 2016 Status changed from recruiting to withdrawn prior to enrolment.
- 17 Nov 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 12 May 2015 According to the ClinicalTrials.gov record, planned initiation date changed from 1 Jan 2015 to 1 Jun 2015.